SK bioscience and GlaxoSmithKline (GSK) have reported that their recombinant, protein-based, Covid-19 vaccine candidate, SKYCovione (GBP510/GSK adjuvant) met the coprimary goals in the Phase III clinical trial.

A self-assembled nanoparticle vaccine candidate, SKYCovione acts on the receptor-binding domain of the Spike protein of the SARS-CoV-2 virus.

The vaccine candidate is also adjuvanted with the pandemic adjuvant of GSK.

Furthermore, the companies have submitted a biologics license application (BLA) for SKYCovione to the Korean Ministry of Food and Drug Safety (KMFDS) following the results.

An advanced purchase agreement is in place with Korea CDC to deliver ten million doses of the vaccine.

In August last year, the companies commenced the Phase III trial to evaluate the safety and immunogenicity of the vaccine.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

SK bioscience carried out a Phase III clinical trial enrolling 4,037 adult subjects aged over 18 years in Thailand, Vietnam, New Zealand, Ukraine, the Philippines and South Korea. 

According to the findings, the vaccine was found to have enhanced neutralising antibody titres compared with AstraZeneca‘s Covid-19 vaccine, Vaxzevria. 

In addition, the SKYCovione vaccine was demonstrated to have a clinically favourable safety profile with most of the adverse reactions following vaccination being found to be mild or moderate.

Two weeks following the second dose, this vaccine also had 2.93 times superior neutralising antibody response against the SARS-CoV-2 parental strain versus the control vaccine. 

Nearly 98.06% of subjects in the SKYCovione arm were seroconverted compared to 87.30% in the control arm.

GSK Vaccines president Roger Connor said: “As the Covid-19 pandemic continues to evolve, a variety of vaccines will be needed to meet the health needs across the globe, including temperature stable vaccines like the SK/GSK vaccine candidate. 

“These immunogenicity and safety data confirm the important role that our adjuvant technologies play in vaccine development.”

SK bioscience plans to seek an emergency use listing (EUL) from the World Health Organization (WHO) and additional authorisations from various regulatory authorities globally.